The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.
Biognosys is the world leader in next-generation proteomics contract research services to support pharma and biotech research and clinical development.
Our software solutions for proteomics include Spectronaut® for DIA proteomics, SpectroDive™ for Targeted Proteomics, SpectroMine™ for DDA proteomics, and our free-of-charge QC tool QuiC™.
Library-free and machine learning-augmented data analysis with Spectronaut® 18 yields industry-leading protein quantification and throughput for DIA proteomics. Novel[...]READ MORE
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the appointment of Jakob Vowinckel, Ph.D., as Chief Officer of[...]READ MORE
Spectronaut® 18 solves most of the pain points of modern mass spectrometry-based projects. The new version is cloud-ready and comes with long-awaited Linux support. But that’s[...]READ MORE
Biognosys, a leading innovator and provider of proteomics solutions, today at the American Society for Mass Spectrometry (ASMS) Annual Conference is announcing the launch of an[...]READ MORE
New R&D workflow achieved a total depth of over 14,600 proteins across 22 different human tissues. In the R&D study, the Bruker timsTOF HT mass spectrometer was deployed[...]READ MORE
Spectronaut® 18 makes DIA proteomics projects more efficient and scalable than ever for all mass spectrometry instrument types. Novel research with TrueDiscovery™[...]READ MORE
In collaboration with prominent biopharma companies and academic institutions, Biognosys will demonstrate the technological advances and versatility of the TrueDiscovery™,[...]READ MORE
New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics, expected to[...]READ MORE